Endocrinology

Medtronic's MiniMed 670G Insulin Pump System alleviates a huge patient burden for T1D patients and gives hope for a similar device for T2D.

The study found that 5.6% of all incident cancers from 5 years ago were attributable to the combined effects of diabetes and high BMI.

Continuous glucose monitoring was shown to lower the risk of hyperglycemia compared to capillary glucose monitoring alone.

OZEMPIC, a GLP-1 receptor agonist, was tested in 2-year cardiovascular outcome trials.

Reddit's Ask Me Anything forums have proven to give physicians a chance to connect with and educate thousands of people at once.

With a dozen-plus agent classes for diabetes, what do physicians address first in patients?

Average daily blood glucose during the study was 152 mg/dL, down from 71 mg/dL - or 32% - from the average admission blood glucose, and below the goal range.

Lifestyle modification was associated with a relative risk reduction of 39% compared to 36% for medications.

To image or not to image: A new study validates professional society recommendations on follow-up strategies for adrenal masses. 

Carlos Grilo, PhD, explains what sort of biases obese and binge-eating disorder patients suffer in pubic and health care settings, and how doctors can re-adjust their approach.

Eliot Brinton, MD, President of the Utah Lipid Center, explains the potential of liraglutide, semaglutide, and it's related therapies for type 2 diabetes.

The AACE/ACE 2017 recommendations on lipid management renew focus on LDL-C targets, and go far lower than any group has ventured to date.

Janssen's T2D drug for CV risks is undergoing a kidney disease-based phase 3 trial now.

FDA sends response letter for deficiencies found in Antares Pharma’s QuickShot Testosterone auto injector.

James Underberg, MD, President-Elect of the National Lipid Association, Clinical Assistant Professor of Medicine, NYU School of Medicine, NYU Center for the Prevention of Cardiovascular Disease, discusses statin intolerance and the future of cholesterol treatments.

The Certified Nurse Practicioner from the Henry Ford Medical Center also weighs in the best advice to avoid cardiovascular disease.

The FreeStyle Libre Flash Glucose Monitoring System reduces the requirement of “fingerstick” testing, with small sensor wire that continuously monitors and measures levels.

The New York University clinical professor of medicine also shared his thoughts on the future of cardiovascular disease medicine.

The Glucommander software showed patients were able to rapidly control their glucose levels and maintain their control long-term.

While previous research has shown a link between eating meat and the risk of developing type 2 diabetes, a new study is the first to evaluate the risk in people eating an eastern diet.

Patient-driven doses led to 67.5% of subjects reaching target HbA1C compared to 58.4% in the physician-driven arm.

After adjusting for comorbidities, education level, birthplace, and duration of diabetes, the data showed that men with T1D faced a slightly higher risk of AFib, but women with T1D faced a 50% higher risk of developing AFib.

The genomes associated with a higher risk of CHD are also associated with higher T2D risk, revealing the possibility of a treatment for both.

Sanofi’s dual SGLT1 and SGLT2 inhibitor was statistically significantly superior to placebo in patients with type 1 diabetes (T1D) on background insulin therapy.

A substance known as epicatechin monomers helps the body release more insulin and respond more efficiently to increased blood glucose, which could in turn benefit type 2 diabetics.

Patients in the combination arm also reached the target HbA1c level faster than those using just the single treatment therapy.

Previous guidelines indicated bypass surgery is preferable for diabetics generally, but new research sought to find out if the same held true for the relatively small number of type 1 diabetics.

Women with type 1 diabetes carry a higher risk of AFib than both men and the general public as a whole.

The drug, produced by Sanofi, was granted approval based on the physiochemical, non-clinical, and clinical similarity to another, already approved insulin lispro injection.